03 March 2002
Well-Known Member
- Joined
- 9 Oct 2020
- Messages
- 236
- Team supported
- Manchester City
The lack of a wider vaccine portfolio is unfortunately a sign of the times. Typically diseases requiring vaccines affect the poorest countries and therefore the financial appetite is not there to develop those vaccines. MedImmune/AZ are more than capable of developing and delivering a vaccine from a technical and operational standpoint.Squares with what I wrote yesterday, if rather more sensationally put.
The FDA wants full phase 3 data on the lower dose alone before deciding.
MHRA (and EMA) will probably approve using the data across both doses, but will need to choose which dose if that's the case.
No idea on the details, but a breakdown in relations with FDA seems very likely - there has to be a reason why they paused the trial for so much longer than any other agency.
AZ does, indeed have limited vaccine experience, just one (FLUMIST) on the market. Their part is more for clinical trials experience and manufacturing knowhow.
Note that even this article still expects approval in the US early next year.
My bottom line: that data in the lancet looks good and safe at either dose.
I'd echo your statements about breakdown of relationship with FDA. As we come to the end of this administration it's clear that people are getting fed up and just staying amicable until the next administration. Just recently Pfizer refused Trump's invitation to the WH to discuss vaccine approval.
I understand there is just one outstanding question from the MHRA, I don't know the nature of it but I'd guess it's down to the dosing situation.
Great post as usual.
